Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved a label update for Winrevair (sotatercept) to include its benefit in adults recently diagnosed with pulmonary arterial hypertension (PAH). Based on the phase 3 HYPERION trial, the drug significantly cut the risk of clinical worsening events in newly diagnosed patients — a meaningful step toward earlier, more aggressive treatment in this life-threatening condition.
The FDA has greenlit a label expansion for Winrevair (sotatercept, Merck), now covering adults diagnosed with pulmonary arterial hypertension (PAH) within the past year. Previously approved for PAH broadly in March 2024 and for advanced PAH in October 2025, this latest update reflects a growing push to treat PAH earlier and more aggressively.
The update is backed by the phase 3 HYPERION trial, which enrolled 320 adults with PAH functional class II or III at intermediate-to-high risk of death. The trial was stopped early due to overwhelmingly positive results — only 10.6% of Winrevair patients experienced a first clinical worsening event, compared to 36.9% in the placebo group over a median follow-up of 13.2 months.
By the Numbers:
Why it matters: PAH is a progressive, life-threatening form of heart failure, and early intervention is critical. This label update — aligned with the 2026 ERS PAH treatment guidelines — gives clinicians a stronger evidence base to deploy Winrevair sooner in a patient's disease course, potentially improving long-term outcomes and quality of life.
